Colleen Moretti

Colleen Moretti, Assistant Editor for CURE®, joined MJH Life Sciences in November 2020. Colleen is a graduate of Monmouth University, where she studied communication with a focus in journalism and public relations. In her free time, she enjoys learning to cook new meals, spending time with her adopted beagle, Molly, or sitting on the beach with a good book. Email her at cmoretti@curetoday.com


Chemotherapy Combination May Significantly Prolong Survival for Certain Patients With Pancreatic Cancer

September 15, 2022

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all patients may not be suitable for this treatment, an expert said.

Trodelvy Elicits Significant Survival Improvement in A Group of Patients With Pre-Treated Metastatic Breast Cancer

August 16, 2022

The use of Trodelvy was associated with a significant improvement in survival when compared with physician’s choice of chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer, according to recently announced study findings.

Patient Enrollment Expands in Trial Evaluating Novel Drug in Breast Cancer

August 12, 2022

After findings from an early-phase trial showed that the novel drug was associated with anti-tumor activity, investigators decided to continue enrolling more patients with ER-positive, HER2-negative metastatic breast cancer.

Patients With MPNs Must Be Honest About Their Symptoms, Says Expert

June 20, 2022

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.